GlassScriptPhysician profile
Alan N Bunney
NPI 1427391135
$4,542.94
in general payments reported to CMS, 2019-2025
43 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $715 · 2021: $438 · 2022: $227 · 2023: $957 · 2024: $423 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $560.11 | 2019-2025 | Vraylar, Linzess, Viberzi |
| Pfizer INC. | $506.60 | 2019-2025 | |
| Amgen INC. | $346.46 | 2019-2025 | Evenity, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $316.55 | 2019-2025 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $282.77 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $280.42 | 2019-2022 | |
| Glaxosmithkline, LLC. | $246.74 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $191.98 | 2019 | |
| Novo Nordisk INC | $187.89 | 2019-2025 | Ozempic, Rybelsus |
| Astellas Pharma US INC | $154.17 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.67 | 2019-2021 | |
| Horizon Therapeutics Plc | $97.21 | 2019-2022 | |
| Abbott Laboratories | $95.24 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $85.24 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.28 | 2020-2023 | Xifaxan |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $67.35 | 2019-2020 | |
| Corium, LLC | $65.07 | 2023 | Adlarity, Azstarys |
| Sanofi-Aventis U.S. LLC | $62.68 | 2019-2023 | |
| Impel Pharmaceuticals INC. | $61.31 | 2023 | Trudhesa |
| Sanofi Pasteur INC. | $60.97 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $50.40 | 2023 | Quviviq |
| Esperion Therapeutics, INC. | $50.34 | 2021-2024 | Nexletol |
| Axsome Therapeutics, INC. | $48.01 | 2023 | Sunosi |
| Boston Scientific Corporation | $44.64 | 2023-2025 | Watchman Flx |
| Sumitomo Pharma America, INC. | $42.30 | 2024 | Gemtesa |
| Amarin Pharma, INC. | $38.16 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $37.84 | 2025 | Rexulti |
| Amneal Pharmaceuticals LLC | $36.82 | 2019-2023 | Unithroid |
| Exact Sciences Corporation | $35.71 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $35.09 | 2023 | |
| Lilly USA, LLC | $29.62 | 2021-2023 | Mounjaro, Zepbound |
| Kyowa Kirin, INC. | $29.54 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.59 | 2025 | Caplyta |
| Lundbeck LLC | $22.74 | 2023 | Rexulti |
| Inari Medical, INC. | $19.52 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Jazz Pharmaceuticals INC. | $19.04 | 2025 | |
| Daiichi Sankyo INC. | $17.09 | 2019 | |
| Abiomed | $15.53 | 2024 | Impella |
| Mylan Specialty L.P. | $14.65 | 2019 | |
| Viatris Specialty LLC | $13.82 | 2025 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $12.39 | 2021 | |
| Bioventus LLC | $12.07 | 2019 | |
| Circassia INC. | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Bunney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.